







































IGF = insulin-like growth factor; IL = interleukin; MMP = matrix metalloprotease; PGE = prostaglandin E; TGF = transforming growth factor.
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Introduction
The Novartis–ILAR Rheumatology Prize was awarded at
the 20th ILAR Congress of Rheumatology in Edmonton,
Canada in August 2001. The Editors-in-Chief would like to
inform readers that this Commentary has not undergone
peer-review, because it is based upon the acceptance
speech for the Prize.
Metalloproteases and their inhibitors
In our work on osteoarthritis, we identified several enzy-
matic pathways that are intimately related to the develop-
ment of this disease. More specifically, we demonstrated
that, although the matrix metalloprotease (MMP) family is
of pivotal importance in the degradation of osteoarthritic
cartilage [1–26] (Fig. 1), the serine- and cysteine-depen-
dent proteases [27–30] also play a significant role. We
were among the first to introduce and demonstrate the
importance of an imbalance in enzymes and their specific
inhibitors (tissue inhibitor of MMP, cathepsin B-inhibitors
and plasminogen activator/plasmin/plasminogen activator
inhibitor-1) in osteoarthritic tissues. This concept is now
well recognized as an intimate element in the pathogene-
sis of osteoarthritis.
In recent years, we have been involved in the discovery of
a new collagenase, collagenase-3 (MMP-13), in cartilage
and demonstrated its involvement in the osteoarthritis
disease process [18]. We were also the first group to
clone human collagenase-3 promoter, more specifically its
5′ flanking region (GenBank #U52692) [20]. From the
work undertaken in our laboratory, we have come to the
hypothesis that collagenase-3, in contrast to collagenase-
1 (MMP-1), is involved in the remodeling phase of
osteoarthritic cartilage [21–24,26]. Moreover, we also
found that, although many cytokines and factors can
upregulate collagenase-3, transforming growth factor
(TGF)-β appears to be the factor responsible for its upreg-
ulation in vivo in osteoarthritic cartilage [21,24,26].
Altogether, these findings have proven to be of utmost
importance, as some pharmaceutical companies have tar-
geted MMP and tissue inhibitor of MMP as effective ways
Commentary
The Novartis–ILAR Rheumatology Prize 2001
Osteoarthritis: from molecule to man
Jean-Pierre Pelletier and Johanne Martel-Pelletier
Osteoarthritis Research Unit, Centre Hospitalier de l’Université de Montréal (CHUM) — Hôpital Notre-Dame, Montréal, Québec, Canada
Correspondence: Jean-Pierre Pelletier, MD, Osteoarthritis Research Unit, Centre Hôspitalier de l’Université de Montréal (CHUM) — Hôpital Notre-
Dame, 1560 rue Sherbrooke Est, Montréal, Québec, Canada H2L 4MJ. Tel: +1 514 890 8000 ext. 26658; fax: +1 514 412 7582; 
e-mail: dr@jppelletier.ca
Abstract
During our careers, we have developed new and innovative concepts pertaining to the pathophysiology
of osteoarthritis which have assisted in the development of new therapeutic approaches. Moreover, our
laboratory has long sought to develop protective agents for osteoarthritic structural joint tissues. The
most significant concepts that have originated from our lab are briefly outlined in this commentary.
Keywords: joint articular tissue, magnetic resonance imaging, osteoarthritis, therapeutic
Received: 26 September 2001
Accepted: 4 October 2001
Published: 2 November 2001
Arthritis Res 2002, 4:13-19
© 2002 BioMed Central Ltd
(Print ISSN 1465-9905; Online ISSN 1465-9913)Arthritis Research    Vol 4 No 1 Pelletier and Martel-Pelletier
to prevent osteoarthritis progression. Moreover, it appears
that a specific blockage of collagenase-3 is the preferred
candidate in osteoarthritic patients.
Insulin-like growth factor 1
Since there is a dysregulation between matrix synthesis
and degradation in cartilage affected by osteoarthritis,
researchers have been seeking factors that favor the for-
mation of a durable functional articular surface following
damage. Because of its properties, we studied the involve-
ment of insulin-like growth factor-1 (IGF-1) in cartilage and
bone [31–39]. Our studies revealed the identification of a
metabolic disorder associated with the development of
osteoarthritis. We showed that, although more IGF-1 is
secreted by osteoarthritic chondrocytes, these cells are
hyporesponsive to this growth factor. This phenomenon
was not related to a change in IGF-1-receptor expression
but rather to an increase in IGF-1 binding proteins that
affects the bioavailability of IGF-1. Further studies showed
that prostaglandin E2 (PGE2) upregulated the levels of
IGF-1-binding proteins.
Transforming growth factor ß
We also investigated TGF-β in osteoarthritic cartilage and
most specifically its effect on collagenase-3 upregulation.
Interestingly our data revealed that TGF-β acts in a differen-
tial manner in regulating collagenase-1 (MMP-1) and colla-
genase-3 (MMP-13). Indeed TGF-β1 and -β2 have an
identical pattern in the upregulation of collagenase-3 (MMP-
13), which depends on the metabolic state of the chondro-
Figure 1
Pathways involved in the osteoarthritis disease process. The evolution of the osteoarthritis disease process is characterized by cartilage
degradation caused, at least in part, by proteolytic breakdown of macromolecules, in which matrix metalloproteases (MMPs) play an important role.
Further fibrillation and erosion of the cartilage surface result in the release of molecular breakdown products into the synovial fluid. The
phagocytosis of cartilage matrix breakdown products and other materials by synovial macrophages induces an inflammatory reaction in the synovial
membrane, thereby resulting in local synthesis of proteases and proinflammatory cytokines. The proteases and cytokines released by the synovium
diffuse through the synovial fluid and into the cartilage. They induce additional cartilage breakdown by direct macromolecule proteolysis and by
stimulation of chondrocyte cytokine production to increase the synthesis of proteases. There is also an increased level of cytokine receptors on the
cell. ICE = interleukin-1β-converting enzyme; IL = interleukin; MT-MMP = membrane-type matrix metalloprotease; TIMP = tissue inhibitor of matrix
metalloprotease; u-PA = urokinase plasminogen activator; – refers to inhibition; + to stimulation. A part of this figure was adapted from figure







































cytes [24]. In contrast, TGF-β1 upregulates collagenase-1
(MMP-1) and this was not dependent on the metabolic
state of the cells. TGF-β2 has no effect on this enzyme. In
addition, we recently provided evidence that, in human
osteoarthritic cartilage, extracellular activation of TGF-β
appears to be controlled by the furin convertase [26].
Proinflammatory cytokines
As a result of the work on the enzymes, and more specifi-
cally on MMPs, it became clear that the enzymatic alter-
ations could explain the exhaustive degradation of the
articular joint tissue. However, this did not provide an
explanation for the increased synthesis and expression of
these enzymes and the decreased production of their
inhibitors. Another hypothesis that was brought forth, and
was a turning point in the understanding of the pathophys-
iology of osteoarthritis, is the involvement of synovial mem-
brane inflammation. This hypothesis was based on the
demonstration of the prime role of the proinflammatory
cytokine interleukin (IL)-1β in this disease [40–48].
In addition to demonstrating that IL-1β is responsible, at
least in part, for the changes seen in osteoarthritic joint
tissues [41,42,45,48,49], we documented the mecha-
nisms by which IL-1β stimulates osteoarthritic cell-biologi-
cal activity and how this process was modulated. This led
to the study of IL-1 receptors (IL-1Rs) as well as to the
study of its natural antagonist, IL-1Ra [44,50–56]. In brief,
data showed that IL-1β was the major autocrine proinflam-
matory cytokine involved in the stimulation of catabolic
factors, including MMPs. The data also revealed that the
type I IL-1R was responsible for mediating the IL-1 activity,
the number of this receptor type significantly increased in
osteoarthritic cells [44,50,53]. These findings introduced
the hypothesis that specifically blocking the activity of
IL-1β would protect against structural changes in osteo-
arthritis.
A relative deficit of IL-1Ra vis-à-vis IL-1β was also found in
the diseased tissue, and it was shown that the use of
IL-1Ra could reduce IL-1β-induced cartilage degradation 
[54–56]. In fact, we demonstrated in vivo (by intra-articu-
lar injections of recombinant IL-1Ra in an experimental OA
animal model) that the elevated IL-1Ra level in joint tissues
reduces the progression of this disease. Since the admin-
istration of proteins is a major weakness for drug delivery,
we pursued our research by using gene therapy as a novel
therapeutic approach. In vivo studies using two experi-
mental animal models and two different strategies were
conducted. The first employed an indirect, or ex vivo,
approach in which the IL-1Ra gene was transferred in
vitro into the synoviocytes with the use of an adenovirus
vector, and the transfected cells reintroduced into the
joint. The second used a direct, in vivo, gene transfer uti-
lizing a liposome complexed with a DNA plasmid encoding
the IL-1Ra gene. Collectively, data demonstrated that the
IL-1Ra gene can be transfected into osteoarthritic cells
and produce an IL-1Ra protein that results in a significant
reduction in the progression of the disease. We are cur-
rently increasing our knowledge of gene therapy for its
eventual use in human osteoarthritis.
Recently, we also demonstrated that the specific enzyme
responsible for the extracellular release of active IL-1β, the
IL-1β-converting enzyme (ICE), was present in both
human cartilage and synovial membrane, and its level sig-
nificantly increased in osteoarthritic tissues [57]. We also
showed that ICE-specific inhibition in human osteoarthritic
cartilage resulted in a complete abrogation of active IL-1β
formation. These findings support the notion that blocking
this enzyme represents another interesting potential target
for osteoarthritis therapy.
Recent work in our laboratory strongly points to the fact
that the peroxisome proliferator-activated receptor gamma
(PPARγ) system may represent a therapeutic target in
osteoarthritis [58,59]. Indeed, we showed in human
osteoarthritic chondrocytes and synovial fibroblasts that
PPARγ ligands inhibit IL-1β-induced production of MMPs
and nitric oxide (NO); this occurred at the transcriptional
level.
Nitric oxide
Our work also ascertained that another factor, the
inducible form of nitric oxide synthase (iNOS), is an
extremely important element in regard to the pathophysiol-
ogy of osteoarthritis [60–65] (Fig. 2). We showed that
there is excess production of NO in osteoarthritic cartilage
that is generated via an increase in the iNOS level. NO
also appears to be responsible for inducing many of the
catabolic pathways responsible for osteoarthritic cartilage
degradation, such as the reduction of IL-1Ra. Very impor-
tantly, we recently demonstrated in vivo the potential for
the selective inhibition of iNOS to reduce the progression
of osteoarthritis in an animal model [61,62,64]. The in vivo
inhibition of iNOS reduced the severity of structural joint-
tissue changes, which was associated with a reduction of
MMPs in articular cell tissues and chondrocyte apoptosis,
as well as a reduction in the levels of IL-1β and PGE2 in
synovial fluid [62,64]. Recently, we demonstrated that
exogenous PGE2 may sensitize human osteoarthritic
chondrocytes to cell death induced by NO [65,66]. These
latter data indicate that a possible molecular target for the
inhibition of chondrocyte apoptosis is NO and extracellular
factors involved in signaling.
Subchondral bone
Earlier, we addressed the idea that cytokines are an inter-
esting link in osteoarthritis for tissue cross-talk (synovium–
cartilage) leading to the development and progression of
this disease. As a result of data from morphological and
clinical studies investigating the subchondral bone in
Available online http://arthritis-research.com/content/4/1/013osteoarthritis, it has been proposed that subchondral
bone plays a significant role in the progression of this
disease. A question that still remains to be answered is
whether the changes in subchondral bone induce or only
participate in disease progression.
We recently investigated this concept, and our data pro-
vided new substantiated evidence that subchondral bone
alterations are likely to be related to the onset or progres-
sion of osteoarthritis, rather than being merely consequen-
tial ([30,39,67,68] and our unpublished observations). We
showed that subchondral bone changes are related, at
least in part, to an abnormal subchondral bone osteoblast
metabolism. Some local factors produced by subchondral
bone osteoblasts, such as alkaline phosphatase, osteocal-
cin, plasminogen activator/plasmin and IGF-1 systems, and
cytokines such as IL-6, as well as PGE2 and TGF-β, were
shown to be associated with osteoarthritis progression.
Therapeutic intervention in humans
Following our in vitro and  in vivo data on humans 
[19,69–74] and the in vivo data on animal models 
[5,49,75,76], we further explored in humans the in vivo
effects of intra-articular injections of glucocorticoids. Even
though glucocorticoid injections have been used success-
fully for decades to relieve osteoarthritic symptoms and
restore function, there is still debate about whether this
drug class has a significant effect on disease progression.
We conducted a two-year, double-blind, placebo-con-
trolled study on knee osteoarthritis patients, evaluating the
effect of steroids on osteoarthritic symptoms, quality of life
and disease progression [77]. Data revealed that repeated
steroid injections were found effective for the long-term
symptomatic treatment of knee osteoarthritis without
having any deleterious effects on the anatomical structure
of the joint. Using existing methods to evaluate disease
progression, we were not able in this study to see
changes even in the placebo group.
We then addressed the question of sensitive and accurate
methods for the assessment of the progression of struc-
tural changes in osteoarthritic joints in humans when
looking at the effect of a drug. Visualization of articular car-
tilage is now possible with magnetic resonance imaging
but quantification of this tissue volume was lacking. We
have developed a novel imaging system assessing carti-
lage volume/thickness using magnetic resonance imaging
of the knee. Preliminary data revealed that statistically sig-
nificant changes in the volume and thickness of
osteoarthritic knee cartilage were detectable at 12 months
[78,79], which is a considerable improvement over exist-
ing X-ray techniques. This technology should significantly
improve the investigation of new drugs and their potential
to modify the progression of osteoarthritis.
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Figure 2
Pathways of nitric oxide (NO) formation and effects on articular chondrocytes. COX = cyclooxygenase, IL-1Ra = interleukin-1 receptor antagonist,
iNOS = inducible nitric oxide synthase, NF = nuclear factor, PGs = prostaglandins, – refers to inhibition; + to stimulation. Reproduced from figure
110.3 with permission from [80]. Conclusion
Our research has assisted in the advancement of our
knowledge of the mechanisms leading to joint destruction
in osteoarthritis. At the same time, we have laid the
groundwork for the testing of therapeutic interventions in
vivo  that may be extended to humans. Moreover, the
development of software quantifying the volume and thick-
ness of human cartilage as assessed by magnetic reso-
nance imaging will dramatically change the manner in
which knee osteoarthritis clinical trials are conducted.
Studies will be performed in a timely fashion, allowing the
testing of a larger number of molecules that have the
potential to retard or stop the progression of the disease.
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